Table 9:
Outcomes of Ranibizumab Versus Bevacizumab Re-Treatment Strategies for n-AMD in RCTs
| Study Group | Δ ETDRS BCVA Letters Mean ± SD 1 Year (2 Years) | Proportion (%) Gaining ≥ 15 BCVA Letters over 1 Year | Proportion (%) Losing ≥ 15 BCVA Letters over 1 Year | Δ CRT μm Mean ± SD 1 Year | Visits and OCT Exams | Injections Mean ± SD 1 Year (2 Years) |
|---|---|---|---|---|---|---|
| CATT (N = 1,208) | ||||||
| Ranibizumab monthly | 8.5 ± 0.8 (8.8 ± 15.9) | 34.2 | 5.6 | –196 ± 176 | Fixed | 11.7 ± 1.5 (22.4 ± 3.9) |
| Ranibizumab PRN | 6.8 ± 0.8 (6.7 ± 4.6) | 24.9 | 4.6 | –168 ± 186 | Fixed | 6.9 ± 3.0 (12.6 ± 6.6) |
| Bevacizumab monthly | 8.0 ± 1.0 (7.8 ± 15.5) | 31.3 | 6.0 | –164 ± 181 | Fixed | 11.9 ± 1.2 (23.4 ± 2.8) |
| Bevacizumab PRN | 5.9 ± 1.0 (5.0 ± 17.9) | 28.0 | 8.0 | –152 ± 178 | Fixed | 7.7 ± 3.5 (14.1 ± 7.0) |
| MANTRA (N = 321) | ||||||
| Ranibizumab PRN | 4.9 | NR | NR | –89.9 | Fixed | 5.8 ± 2.7 |
| Bevacizumab PRN | 4.1 | NR | NR | –86.3 | Fixed | 6.1 ± 2.8 |
| IVAN (N = 628) | ||||||
| Ranibizumab (monthly + PRN) | 6.4 ± 12.8 | 23.0 | 5.0 | –155 ± 182 | Fixed | 10.0 (IQR 6,12) |
| Bevacizumab (monthly + PRN) | 4.7 ± 12.5 | 16.0 | 4.0 | –139 ± 182 | Fixed | 11.0 (IQR 7,12) |
| Monthly (ranibizumab + bevaci zumab) | 6.1 ± 14.1 | 20.0 | 5.0 | –168 ± 189 | Fixed | 12.0 (IQR 11,12) |
| PRN (ranibizumab + bevaci zumab) | 5.0 ± 11.1 | 19.0 | 4.0 | –127 ± 174 | Fixed | 7.0 (IQR 6,9) |
| Subrananian (N = 28) | ||||||
| Ranibizumab PRN | 6.3 | 14.3 | 14.3 | –91 | Fixed | 4 (R, 3–6) |
| Bevacizumab PRN | 7.6 | 33.3 | 0 | –50 | Fixed | 8 (R, 3–12) |
Abbreviations: BCVA, best corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IQR, interquartile range; NR, not reported; OCT, optical coherence tomography; PRN, pro re nata (as needed); R, range; SD, standard deviation.